Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-11-13
2007-11-13
Bragdon, Kathleen Kerr (Department: 1656)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S350000, C514S002600, C514S822000
Reexamination Certificate
active
10855068
ABSTRACT:
The invention provides vitamin k-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.
REFERENCES:
patent: 5009889 (1991-04-01), Taylor, Jr. et al.
patent: 5093317 (1992-03-01), Lewis et al.
patent: 5258288 (1993-11-01), Wydro et al.
patent: 5288629 (1994-02-01), Berkner
patent: 5374617 (1994-12-01), Morrissey et al.
patent: 5504064 (1996-04-01), Morrissey et al.
patent: 5516640 (1996-05-01), Watanabe et al.
patent: 5580560 (1996-12-01), Nicolaisen et al.
patent: 5788965 (1998-08-01), Berkner et al.
patent: 5817788 (1998-10-01), Berkner et al.
patent: 5824639 (1998-10-01), Berkner
patent: 5833982 (1998-11-01), Berkner et al.
patent: 5837843 (1998-11-01), Smirnov et al.
patent: 5847085 (1998-12-01), Esmon et al.
patent: 5861374 (1999-01-01), Berkner et al.
patent: 6017882 (2000-01-01), Nelsestuen
patent: 6071514 (2000-06-01), Grinnell et al.
patent: 6762286 (2004-07-01), Nelsestuen
patent: 0 296 413 (1988-12-01), None
patent: 0 354 504 (1990-02-01), None
patent: 64-085096 (1989-03-01), None
patent: WO 88/10295 (1988-12-01), None
patent: WO 99/20767 (1999-04-01), None
patent: WO 02/70681 (2002-09-01), None
GenBank Accession No. M13232 dated Feb. 13, 1996.
GenBank Accession No. K02435 dated Apr. 27, 1993.
GenBank Accession No. K02059 dated Jan. 8, 1995.
Arnljots et al., “Prevention of experimental arterial thrombosis by topical administration of active site-inactivated factor VIIa”,J. Vasc. Surg.,1997, 25(2):341-346.
“Peregrine's Vasucular Targeting Agent Effective in Combination Cancer Therapy,” at http://www.peregrineinc.com/prelease.asp?id=64200391719, 2 pages, Jun. 4, 2003.
Bauer, “Treatment of Factor VII Deficiency with Recombinant Factor VIIa,”Haemostasis,1996, 26(Suppl. 1):155-158.
Bodner et al., “The Pituitary-Specific Transcription Factor GHF-1 Is a Homeobox-Containing Protein,”Cell,1988, 55:505-518.
Bradford, “A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding,”Analyt. Biochem.,1976, 72:248-254.
Broze Jr. et al., “Monoclonal Anti-human Factor VII Antibodies,”J. Clin. Invest.,1985, 76:937-946.
Cheung et al., “Localization of an Epitope of a Calcium-Dependent Monoclonal Antibody to the N-Terminal Region of the Gla Domain of Human Factor VII,”Thromb. Res.,1995, 79(2):199-206.
Choudhri et al., “Targeted Inhibition of Intrinsic Coagulation Limits Cerebral Injury in Stroke without Increasing Intracerebral Hemorrhage,”J. Exp. Med.,1999, 190:91-99.
Christiansen et al., “Hydrophobic Amino Acid Residues of Human Anticoagulation Protein C That Contribute to Its Functional Binding to Phospholipid Vesicles,”Biochem.,1995, 34:10376-10382.
Dackiw et al., “Prevention of Endotoxin-Induced Mortality by Antitissue Factor Immunization,”Arch. Surg.,1996, 131:1273-1278.
Dahlback, “Inherited Thrombophilia: Resistance to Activated Protein C as a Pathogenic Factor of Venous Thromboembolism,”Blood,85(3):607-614, (1995).
Dickinson and Ruf, “Active Site Modification of Factor VIIa Affects Interactions of the Protease Domain with Tissue Factor,”J. Biol. Chem.,1997, 272(32):19875-19879.
Esmon et al., “Isolation of a Membrane-bound Cofactor for Thrombin-catalyzed Activation of Protein C,”J. Biol. Chem.,1982, 257(2):859-864.
Evans, Jr. and Nelsestuen, “Importance ofcis-Proline 22 in the Membrane-Binding Conformation of Bovine Prothrombin,”Biochemistry,1996, 35:8210-8215.
Evans et al., “How Important are proline 22 and the 41-45 Helical stack to Membrane Binding by Bovine Prothrombin?”Protein Sci.,1996, 5:Suppl. 1, 163, Abstract, #606-S.
Felgner et al., “Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure,”Proc. Natl. Acad. Sci. USA,1987, 84:7413-7417.
Fiore et al., “The Biochemical Basis for the Apparent Defect of Soluble Mutant Tissue Factor in Enhancing the Proteolytic Activities of Factor VIIa,”J. Biol. Chem.,1994, 269(1):143-149.
Freedman et al., “Identification of the Phospholipid Binding Site in the Vitamin K-dependent Blood Coagulation Protein Factor IX”,J. Biol. Chem.,1996, 271(27):16227-16236.
Furie et al., “The Molecular Basis of Blood Coagulation,”Cell,1988, 53:505-518.
Han et al., “Isolation of a protein Z-dependent plasma protease inhibitor,”Proc. Natl. Acad. Sci. USA,1998, 95:9250-9255.
He et al., “Expression and functional characterization of chimeras between human and bovine vitamin-K-dependent protein-S-defining modules important for the species specificity of the activated protein C cofactor activity,”Eur. J. Biochem.,1995, 227:433-440.
Hedner et al., “Recombinant Activated Factor VII in the Treatment of Bleeding Episodes in Patients with Inherited and Acquired Bleeding Disorders,”Transfus. Med. Rev.,1993, 7(2):78-83.
Hope et al., “Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential,”Biochem. Biophys. Acta.,1985, 812:55-65.
Hoskins et al., “Cloning and characterization of human liver cDNA encoding a protein S precursor,”Proc. Natl. Acad. Sci. USA,1987, 84:349-353.
Huang, “Studies on Phosphatidylcholine Vesicles. Formation and Physical Characteristics,”Biochem.,1969, 8(1):344-352.
Humphries et al., “Chemical methods of protein synthesis and modification,”Curr. Opin. Biotechnol.,1991, 2:539-543.
Jurlander et al., “Recombinant Activated Factor VII (rFVIIa): Characterization, Manufacturing, and Clinical Development,”Semin. Thromb. Hemos.,2001, 27(4):373-383.
Kurz et al., “Comparison in an Arteriovenous (AV) Shunt Model of Thrombosis in the Guinea Pig of the Antithrombotic and Anticoagulant Activities of a gl-Domain variant of Human Activated Protein C (APC) with Native APC and with a Low Molecular Weight Heparin (LMWH),” presented at Dec. 2002 meeting of the American Society of Hematology.
Leff, “Genetically Stripped-Down Factor VIII Corrects Bleeding Disorder in Hemophiliac Mice,”BioWorld Today,1997, 8(209):1,6.
Lu and Nelsestuen, “Dynamic Features of Prothrombin Interaction with Phospholipid Vesicles of Different Size and Composition: Implications for Protein-Membrane Contact,”Biochemistry,1996, 35:8193-8200.
Lu and Nelsestuen, “The Prothrombinase Reaction: “Mechanism Switching” between Michaelis-Menten and Non-Michaelis-Menten Behaviors,”Biochem.,1996, 35(25):8201-8209.
Martinez et al., “Underdecarboxlyation of Vitamin K-Dependent Proteins: Occasionally Severe, Possibly Universal,” Proceedings of the 49th ASMS Conference on Mass Spectrometry and Allied Topics, May 27-31, 2001, Chicago, Illinois, 2 pgs.
Matsubara et al., “A Receptor Tyrosine Kinase, Sky, and Its Ligand Gas 6 are Expressed in Gonads and Support Primordial Germ Cell Growth or Survival in Culture,”Dev. Biol.,1996, 180:499-510.
Mayer et al., “Prothrombin Association with Phospholipid Monolayers,”Biochemistry,1983, 22(2):316-321.
McDonald et al., “Comparison of Naturally Occuring Vitamin K-Dependent Proteins: Correlation of Amino Acid Sequences and Membrane Binding Properties Suggests a Membrane Contact Site,”Biochem.,1997, 36:5120-5127.
McDonald et al., “Ionic Properties of Membrane Association by Vitamin K-Dependent Proteins: The Case of Univalency,”Biochem.,1997, 36(50):15589-15598.
Morrissey et al., “Quantitation of Activated Factor VII Levels in Plasma Using a Tissue Factor Mutant Selectively Deficient in Promoting Factor VII Activation,”Blood,1993, 81(3):734-744.
Muir and Kent, “The chemical synthesis of proteins,”Cu
Bragdon Kathleen Kerr
Fish & Richardson P.C.
Regents of the University of Minnesota
Schnizer Holly
LandOfFree
Modified vitamin K-dependent polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified vitamin K-dependent polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified vitamin K-dependent polypeptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3859929